Incyte (INCY) Q1 2025 earnings summary

Executive summary

• Q1 2025 total revenues reached $1.05 billion, up 20% year-over-year, with product revenues at $922 million (+26% YoY), driven by Jakafi, Opzelura, and the launch of Niktimvo.

• Jakafi net product revenue was $709 million (+24% YoY); Opzelura $119 million (+38% YoY); Niktimvo contributed $14 million in its first quarter.

• Strong pipeline progress with positive pivotal and proof-of-concept data for povorcitinib in hidradenitis suppurativa and CSU, and bioequivalence for ruxolitinib XR.

• Four product launches are planned for 2025, with Niktimvo already launched and three more expected.

• U.S. and international expansion continued, with regulatory approvals and new launches for key products.

Financial highlights

• GAAP net income was $158 million; Non-GAAP net income was $229 million for Q1 2025.

• GAAP operating income increased 123% YoY to $205 million; Non-GAAP operating income rose 76% to $284 million.

• Cash, cash equivalents, and marketable securities totaled $2.4 billion as of March 31, 2025.

• Operating expenses were $848 million (+7% YoY); R&D expenses were $437 million (+2% YoY); SG&A expenses were $326 million (+8% YoY).

• Diluted EPS was $0.80 (GAAP), $1.16 (Non-GAAP), both up from Q1 2024.

Outlook and guidance

• Full-year 2025 Jakafi net product revenue guidance raised to $2.95–3.0 billion.

• Opzelura guidance at $630–$670 million; other Hem/Onc guidance unchanged at $415–$455 million.

• Multiple upcoming milestones in 2025, including three additional launches, pivotal trial readouts, and proof-of-concept results.

• Approvals for pediatric atopic dermatitis and new oncology indications anticipated in H2 2025.

• Ongoing investments in R&D and commercial infrastructure to support pipeline and global expansion.